Real‐World Effectiveness and Safety of GLP ‐1 Receptor Agonists Among Patients With Weight Recurrence After Bariatric Surgery
Obesity · 2026
DOI: 10.1002/oby.70280 ↗At a glance
Journal article in Obesity, 2026. Written by Tarik Yuce and 9 co-authors. Institution: Surgical Outcomes and Quality Improvement Center (SOQIC), Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA. Major MEDLINE topics: Glucagon-Like Peptide-1 Receptor Agonists, Bariatric Surgery, Weight Loss. 26 references. Funded by: NIDDK NIH HHS, NICHD NIH HHS, NIH/NIDDK.
Abstract (original language)
Objective
This study assessed glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) effectiveness and safety in adults with weight recurrence after metabolic and bariatric surgery (MBS).
Methods
We conducted a retrospective new‐user cohort study using OneFlorida+ Data Trust (2015‐2024) among adults with ≥ 10% post‐MBS weight recurrence. GLP‐1 RA users were matched to non‐users on BMI and timing of clinical encounter; the index date was defined as GLP‐1 RA initiation for users and a matched reference date for non‐users. Inverse probability of treatment weighting was applied to further control for confounding. Effectiveness was measured as percentage of recurrent weight lost [(index weight − follow‐up weight) ÷ (index weight − nadir weight) × 100] at 6 and 12 months; safety outcomes included gastrointestinal and post‐MBS adverse events. Effectiveness was compared using t ‐tests, and safety was assessed using Cox proportional hazards models.
Results
Among patients with ≥ 10% weight recurrence, 68 GLP‐1 RA users and 131 non‐users were included at 6 months, and 72 users and 139 non‐users were included at 12 months. GLP‐1 RA users lost significantly more recurrent weight at 6 months (9.6% vs. 4.3%, p = 0.005) and 12 months (14.8% vs. 8.1%, p = 0.017), with no increased risk of adverse events at either time point.
Conclusions
Among adults with post‐MBS weight recurrence, GLP‐1 RAs were associated with greater weight loss without increased adverse events.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Surgical Outcomes and Quality Improvement Center (SOQIC), Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
- Department of Pharmacy Practice, College of Pharmacy, Purdue University, Indianapolis, Indiana, USA.
- Department of Biostatistics & Health Data Science, Indiana University, Indianapolis, Indiana, USA.
- Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.
- Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, Florida, USA.
ORCID profiles: Rotana M Radwan
Funding
- NIDDK NIH HHS
- NICHD NIH HHS
- NIH/NIDDK
- National Institute of Diabetes and Digestive and Kidney Diseases
Cite
APA
Yuce, T., Radwan, R. M., Lee, Y. A., Holler, E., Dai, H., He, X., Huang, Y., Guo, Y., Bian, J., & Guo, J. (2026). Real‐World Effectiveness and Safety of GLP ‐1 Receptor Agonists Among Patients With Weight Recurrence After Bariatric Surgery. Obesity. https://doi.org/10.1002/oby.70280
Vancouver
Yuce T, Radwan RM, Lee YA, Holler E, Dai H, He X, et al. Real‐World Effectiveness and Safety of GLP ‐1 Receptor Agonists Among Patients With Weight Recurrence After Bariatric Surgery. Obesity. 2026. doi:10.1002/oby.70280
BibTeX
@article{Yuce2026,
author = {Yuce, Tarik and Radwan, Rotana M and Lee, Yao An and Holler, Emma and Dai, Hao and He, Xing and Huang, Yu and Guo, Yi and Bian, Jiang and Guo, Jingchuan},
title = {Real‐World Effectiveness and Safety of GLP ‐1 Receptor Agonists Among Patients With Weight Recurrence After Bariatric Surgery},
journal = {Obesity},
year = {2026},
doi = {10.1002/oby.70280}
}
EUVIMED